Aspire Health

1. 3. The page suggests discussing retatrutide after a plateau, but does not establish a separately specified, priced program, preparation or pharmacy. This mention is not treated as a verified additional active product or an approval claim. https://aspirehealth.care/semaglutide-for-medical-weight-management/
2. 4. The main weight-loss page explicitly advertises a free new-patient consultation and $49 Monthly Medical Care, while the FAQ states $49 every 28 days. The exact FAQ cycle is retained; a 28-day cycle is not a calendar month. General legal language about consultation fees does not override the explicit free initial consultation offer. https://aspirehealth.care/weight-loss/ https://aspirehealth.care/faq/
3. 5. The fully loaded public map marks these 31 clearly identifiable states blue under its Currently Licensed legend: Alaska, Arizona, Colorado, Florida, Hawaii, Idaho, Illinois, Iowa, Kansas, Kentucky, Louisiana, Maine, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Dakota, Oklahoma, South Dakota, Utah, Vermont, Virginia, Washington, Wisconsin, Wyoming. This is a conservative licensure subset, not an exhaustive roster or confirmation that this medication is available in each state. Tiny Delaware, Maryland and District of Columbia markings were not classified. Drug, provider and pharmacy restrictions still apply; full program coverage is not established. https://aspirehealth.care/service-areas/
4. 6. The current dose table identifies actual compounded medication vials, with one-, two- and three-vial prices and dose-dependent supplies measured in weeks. One-vial prices are recorded without converting weeks to months; multi-vial totals remain source-specific catalog variants. The/B3 heading is printed by the provider; confirm the exact formula on the pharmacy label. https://aspirehealth.care/tirzepatide-for-weight-loss/
5. 7. The page suggests discussing retatrutide after a plateau, but does not establish a separately specified, priced program, preparation or pharmacy. This mention is not treated as a verified additional active product or an approval claim. https://aspirehealth.care/tirzepatide-for-weight-loss/
6. 8. Wegovy is an actual named prescribing option. Its dose table describes four-week supplies, but explicitly says pricing varies with insurance; no universal cash invoice is established. The catalog also lists Ozempic as weekly injectable semaglutide. Neither current public source establishes a dispensed device. https://aspirehealth.care/weight-loss-medications/
7. 9. Zepbound is an actual named prescribing option. Its dose table describes four-week supplies, but explicitly says pricing varies with insurance; no universal cash invoice is established. The catalog also lists Mounjaro as weekly injectable tirzepatide. Neither current public source establishes a dispensed device. https://aspirehealth.care/weight-loss-medications/
8. 10. The original and current catalog identify oral Wegovy at $149/month for 1.5/4 mg or $299/month for 9/25 mg. This is branded semaglutide, not an unidentified oral preparation; the classification is corrected without creating a new launch. Manufacturer prescribing information explicitly identifies Wegovy semaglutide tablets for oral use. https://aspirehealth.care/weight-loss-medications/ https://www.novo-pi.com/wegovy.pdf
9. 11. The current public catalog offers Saxenda with a Schedule Consultation path and describes daily injection. Its medication price varies by insurance and no numerical medication price is published. Manufacturer primary prescribing information identifies liraglutide and subcutaneous injection; no specific device is inferred from provider imagery. https://aspirehealth.care/weight-loss-medications/ https://www.novo-pi.com/saxenda.pdf

September 2026

1. 12. Aspire Health states two different, unreconciled monthly non-medication fees: the semaglutide and tirzepatide product pages each say 'Monthly Medical Care: $49 — Includes provider visits, messaging, prescription management, and ongoing medical support. Medication priced separately (see tables above)', while the FAQ separately describes a 'LoseIt Program' at $75/month whose active enrollment 'is required to continue medication therapy.' Neither page mentions or reconciles the other figure. The membership entry above uses the $75 LoseIt Program figure since it is the one explicitly tied to required enrollment; the $49 'Monthly Medical Care' quote ('Monthly Medical Care: $49') from https://aspirehealth.care/tirzepatide-for-weight-loss/ and https://aspirehealth.care/semaglutide-for-medical-weight-management/ is flagged here rather than recorded a second time. Separately, https://aspirehealth.care/service-areas/ lists 49 state names (every state except Alabama) grouped as 'Western/Central/Eastern States,' but the page explains these are color-coded on an interactive map as 'Currently Licensed' vs. 'Coming Soon' — this text-extraction tool cannot read the map's color-coding, so which of the 49 are actually served today could not be confirmed; states.list is left empty rather than asserting all 49 as current coverage. The Wegovy/Zepbound dose tables are captioned 'Pricing varies based on insurance coverage. Patients should verify benefits directly with their insurance provider,' so it is unclear whether the listed dollar figures are a cash-pay price or already insurance-adjusted; recorded as-is with that caveat rather than labeled 'cash price'.